Literature DB >> 35238971

Multiparametric MRI-based radiomics model to predict pelvic lymph node invasion for patients with prostate cancer.

Haoxin Zheng1,2, Qi Miao3,4, Yongkai Liu1, Sohrab Afshari Mirak1, Melina Hosseiny1, Fabien Scalzo2,5, Steven S Raman1, Kyunghyun Sung1.   

Abstract

OBJECTIVE: To identify which patient with prostate cancer (PCa) could safely avoid extended pelvic lymph node dissection (ePLND) by predicting lymph node invasion (LNI), via a radiomics-based machine learning approach.
METHODS: An integrative radiomics model (IRM) was proposed to predict LNI, confirmed by the histopathologic examination, integrating radiomics features, extracted from prostatic index lesion regions on MRI images, and clinical features via SVM. The study cohort comprised 244 PCa patients with MRI and followed by radical prostatectomy (RP) and ePLND within 6 months between 2010 and 2019. The proposed IRM was trained in training/validation set and evaluated in an internal independent testing set. The model's performance was measured by area under the curve (AUC), sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV). AUCs were compared via Delong test with 95% confidence interval (CI), and the rest measurements were compared via chi-squared test or Fisher's exact test.
RESULTS: Overall, 17 (10.6%) and 14 (16.7%) patients with LNI were included in training/validation set and testing set, respectively. Shape and first-order radiomics features showed usefulness in building the IRM. The proposed IRM achieved an AUC of 0.915 (95% CI: 0.846-0.984) in the testing set, superior to pre-existing nomograms whose AUCs were from 0.698 to 0.724 (p < 0.05).
CONCLUSION: The proposed IRM could be potentially feasible to predict the risk of having LNI for patients with PCa. With the improved predictability, it could be utilized to assess which patients with PCa could safely avoid ePLND, thus reduce the number of unnecessary ePLND. KEY POINTS: • The combination of MRI-based radiomics features with clinical information improved the prediction of lymph node invasion, compared with the model using only radiomics features or clinical features. • With improved prediction performance on predicting lymph node invasion, the number of extended pelvic lymph node dissection (ePLND) could be reduced by the proposed integrative radiomics model (IRM), compared with the existing nomograms.
© 2022. The Author(s), under exclusive licence to European Society of Radiology.

Entities:  

Keywords:  Lymph nodes; Machine learning; Multiparametric magnetic resonance imaging; Prostatectomy

Mesh:

Year:  2022        PMID: 35238971      PMCID: PMC9283224          DOI: 10.1007/s00330-022-08625-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   7.034


  30 in total

1.  Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores.

Authors:  Alberto Briganti; Alessandro Larcher; Firas Abdollah; Umberto Capitanio; Andrea Gallina; Nazareno Suardi; Marco Bianchi; Maxine Sun; Massimo Freschi; Andrea Salonia; Pierre I Karakiewicz; Patrizio Rigatti; Francesco Montorsi
Journal:  Eur Urol       Date:  2011-11-07       Impact factor: 20.096

2.  A new formula for prostate cancer lymph node risk.

Authors:  James B Yu; Danil V Makarov; Cary Gross
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-30       Impact factor: 7.038

3.  External validation of the Memorial Sloan Kettering Cancer Centre and Briganti nomograms for the prediction of lymph node involvement of prostate cancer using clinical stage assessed by magnetic resonance imaging.

Authors:  Timo F W Soeterik; Tom A Hueting; Bas Israel; Harm H E van Melick; Lea M Dijksman; Saskia Stomps; Douwe H Biesma; Hendrik Koffijberg; Michiel Sedelaar; J Alfred Witjes; Jean-Paul A van Basten
Journal:  BJU Int       Date:  2021-05-16       Impact factor: 5.588

Review 4.  The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review.

Authors:  Nicola Fossati; Peter-Paul M Willemse; Thomas Van den Broeck; Roderick C N van den Bergh; Cathy Yuhong Yuan; Erik Briers; Joaquim Bellmunt; Michel Bolla; Philip Cornford; Maria De Santis; Ekelechi MacPepple; Ann M Henry; Malcolm D Mason; Vsevolod B Matveev; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Ivo G Schoots; Thomas Wiegel; Thomas B Lam; Nicolas Mottet; Steven Joniau
Journal:  Eur Urol       Date:  2017-01-24       Impact factor: 20.096

5.  Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer.

Authors:  Waldemar Wilczak; Corinna Wittmer; Till Clauditz; Sarah Minner; Stefan Steurer; Franziska Büscheck; Till Krech; Maximilian Lennartz; Luisa Harms; Diane Leleu; Marc Ahrens; Sebastian Ingwerth; Christian T Günther; Christina Koop; Ronald Simon; Frank Jacobsen; Maria C Tsourlakis; Viktoria Chirico; Doris Höflmayer; Eik Vettorazzi; Alexander Haese; Thomas Steuber; Georg Salomon; Uwe Michl; Lars Budäus; Derya Tilki; Imke Thederan; Christoph Fraune; Cosima Göbel; Marie-Christine Henrich; Manuela Juhnke; Katharina Möller; Ahmed Abdullah Bawahab; Ria Uhlig; Meike Adam; Sören Weidemann; Burkhard Beyer; Hartwig Huland; Markus Graefen; Guido Sauter; Thorsten Schlomm
Journal:  Eur Urol       Date:  2018-06-13       Impact factor: 20.096

6.  Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference.

Authors:  Constantinos Zamboglou; Montserrat Carles; Tobias Fechter; Selina Kiefer; Kathrin Reichel; Thomas F Fassbender; Peter Bronsert; Goeran Koeber; Oliver Schilling; Juri Ruf; Martin Werner; Cordula A Jilg; Dimos Baltas; Michael Mix; Anca L Grosu
Journal:  Theranostics       Date:  2019-04-13       Impact factor: 11.556

7.  Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database.

Authors:  Junru Chen; Zhipeng Wang; Jinge Zhao; Sha Zhu; Guangxi Sun; Jiandong Liu; Haoran Zhang; Xingming Zhang; Pengfei Shen; Ming Shi; Hao Zeng
Journal:  Sci Rep       Date:  2019-11-29       Impact factor: 4.379

8.  Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer.

Authors:  Matthijs C F Cysouw; Bernard H E Jansen; Tim van de Brug; Daniela E Oprea-Lager; Elisabeth Pfaehler; Bart M de Vries; Reindert J A van Moorselaar; Otto S Hoekstra; André N Vis; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-07-31       Impact factor: 9.236

9.  Head-to-Head Comparison of Two Nomograms Predicting Probability of Lymph Node Invasion in Prostate Cancer and the Therapeutic Impact of Higher Nomogram Threshold.

Authors:  Zilvinas Venclovas; Tim Muilwijk; Aivaras J Matjosaitis; Mindaugas Jievaltas; Steven Joniau; Daimantas Milonas
Journal:  J Clin Med       Date:  2021-03-02       Impact factor: 4.241

10.  Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence.

Authors:  Katharina Sprute; Vasko Kramer; Stefan A Koerber; Manuel Meneses; Rene Fernandez; Cristian Soza-Ried; Mathias Eiber; Wolfgang A Weber; Isabel Rauscher; Kambiz Rahbar; Michael Schaefers; Tadashi Watabe; Motohide Uemura; Sadahiro Naka; Norio Nonomura; Jun Hatazawa; Constantin Schwab; Viktoria Schütz; Markus Hohenfellner; Tim Holland-Letz; Juergen Debus; Clemens Kratochwil; Horacio Amaral; Pete L Choyke; Uwe Haberkorn; Camilo Sandoval; Frederik L Giesel
Journal:  J Nucl Med       Date:  2020-08-17       Impact factor: 10.057

View more
  1 in total

1.  Identidication of novel biomarkers in non-small cell lung cancer using machine learning.

Authors:  Fangwei Wang; Qisheng Su; Chaoqian Li
Journal:  Sci Rep       Date:  2022-10-06       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.